BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: von Kügelgen I. Pharmacology of P2Y receptors. Brain Res Bull 2019;151:12-24. [PMID: 30922852 DOI: 10.1016/j.brainresbull.2019.03.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Sophocleous RA, Miles NA, Ooi L, Sluyter R. P2Y2 and P2X4 Receptors Mediate Ca2+ Mobilization in DH82 Canine Macrophage Cells. Int J Mol Sci 2020;21:E8572. [PMID: 33202978 DOI: 10.3390/ijms21228572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gessler S, Guthmann C, Schuler V, Lilienkamp M, Walz G, Yakulov TA. Control of Directed Cell Migration after Tubular Cell Injury by Nucleotide Signaling. Int J Mol Sci 2022;23:7870. [PMID: 35887219 DOI: 10.3390/ijms23147870] [Reference Citation Analysis]
3 Cheng R, Zhu G, Ni C, Wang R, Sun P, Tian L, Zhang L, Zhang J, Ye X, Luo B, Zheng M. P2Y2 Receptor Mediated Neuronal Regeneration and Angiogenesis to Affect Functional Recovery in Rats with Spinal Cord Injury. Neural Plasticity 2022;2022:1-10. [DOI: 10.1155/2022/2191011] [Reference Citation Analysis]
4 Reichert KP, Castro MFV, Assmann CE, Bottari NB, Miron VV, Cardoso A, Stefanello N, Morsch VMM, Schetinger MRC. Diabetes and hypertension: Pivotal involvement of purinergic signaling. Biomed Pharmacother 2021;137:111273. [PMID: 33524787 DOI: 10.1016/j.biopha.2021.111273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tomczyk M, Glaser T, Slominska EM, Ulrich H, Smolenski RT. Purine Nucleotides Metabolism and Signaling in Huntington's Disease: Search for a Target for Novel Therapies. Int J Mol Sci 2021;22:6545. [PMID: 34207177 DOI: 10.3390/ijms22126545] [Reference Citation Analysis]
6 Bagheri S, Saboury AA, Haertlé T. Adenosine deaminase inhibition. Int J Biol Macromol 2019;141:1246-57. [PMID: 31520704 DOI: 10.1016/j.ijbiomac.2019.09.078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Andrejew R, Glaser T, Oliveira-Giacomelli Á, Ribeiro D, Godoy M, Granato A, Ulrich H. Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases. Adv Exp Med Biol 2019;1201:275-353. [PMID: 31898792 DOI: 10.1007/978-3-030-31206-0_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Al-Najjar BO, Saqallah FG, Abbas MA, Al-Hijazeen SZ, Sibai OA. P2Y12 antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies. Eur J Med Chem 2022;227:113924. [PMID: 34731765 DOI: 10.1016/j.ejmech.2021.113924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Bán EG, Brassai A, Vizi ES. The role of the endogenous neurotransmitters associated with neuropathic pain and in the opioid crisis: The innate pain-relieving system. Brain Res Bull 2020;155:129-36. [PMID: 31816407 DOI: 10.1016/j.brainresbull.2019.12.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
10 Ali AAH, Abdel-Hafiz L, Tundo-Lavalle F, Hassan SA, von Gall C. P2Y2 deficiency impacts adult neurogenesis and related forebrain functions. FASEB J 2021;35:e21546. [PMID: 33817825 DOI: 10.1096/fj.202002419RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Prowse N, Hayley S. Microglia and BDNF at the crossroads of stressor related disorders: Towards a unique trophic phenotype. Neurosci Biobehav Rev 2021;131:135-63. [PMID: 34537262 DOI: 10.1016/j.neubiorev.2021.09.018] [Reference Citation Analysis]
12 Afzal S, Al-Rashida M, Hameed A, Pelletier J, Sévigny J, Iqbal J. Synthesis, In-vitro evaluation and molecular docking studies of oxoindolin phenylhydrazine carboxamides as potent and selective inhibitors of ectonucleoside triphosphate diphosphohydrolase (NTPDase). Bioorg Chem 2021;112:104957. [PMID: 34020240 DOI: 10.1016/j.bioorg.2021.104957] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Li Y, Zhang Y, Cao B, Zhang F, Niu M, Bai X, Zhang M, Zhang H. Screening for the antiplatelet aggregation quality markers of Salvia yunnanensis based on an integrated approach. Journal of Pharmaceutical and Biomedical Analysis 2020;188:113383. [DOI: 10.1016/j.jpba.2020.113383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Guan Z, Makled MN, Inscho EW. Purinoceptors, renal microvascular function and hypertension. Physiol Res 2020;69:353-69. [PMID: 32301620 DOI: 10.33549/physiolres.934463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Verkhratsky A, Zimmermann H, Abbracchio MP, Illes P, Divirgilio F. In Memoriam Geoffrey Burnstock: Creator of Purinergic Signaling. Function 2020;1:zqaa006. [DOI: 10.1093/function/zqaa006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Engel T, Sperlagh B. Purinergic signaling as a target for emerging neurotherapeutics. Brain Res Bull 2019;151:1-2. [PMID: 31163189 DOI: 10.1016/j.brainresbull.2019.05.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Vultaggio-poma V, Di Virgilio F. P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells. Biomolecules 2022;12:983. [DOI: 10.3390/biom12070983] [Reference Citation Analysis]
18 Gómez Morillas A, Besson VC, Lerouet D. Microglia and Neuroinflammation: What Place for P2RY12? Int J Mol Sci 2021;22:1636. [PMID: 33561958 DOI: 10.3390/ijms22041636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Pottie E, Storme J, Stove CP. The P2Y2 Receptor C-Terminal Tail Modulates but Is Dispensable for β-Arrestin Recruitment. Int J Mol Sci 2022;23:3460. [PMID: 35408820 DOI: 10.3390/ijms23073460] [Reference Citation Analysis]
20 Ceruti S. From astrocytes to satellite glial cells and back: A 25 year-long journey through the purinergic modulation of glial functions in pain and more. Biochem Pharmacol 2021;187:114397. [PMID: 33382970 DOI: 10.1016/j.bcp.2020.114397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Khalafalla MG, Woods LT, Jasmer KJ, Forti KM, Camden JM, Jensen JL, Limesand KH, Galtung HK, Weisman GA. P2 Receptors as Therapeutic Targets in the Salivary Gland: From Physiology to Dysfunction. Front Pharmacol 2020;11:222. [PMID: 32231563 DOI: 10.3389/fphar.2020.00222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Gawlińska K, Frankowska M, Gawliński D, Piechota M, Korostyński M, Filip M. Cocaine Administration and Its Abstinence Conditions Modulate Neuroglia. Int J Mol Sci 2020;21:E7970. [PMID: 33120991 DOI: 10.3390/ijms21217970] [Reference Citation Analysis]
23 Serafini M, Cargnin S, Massarotti A, Tron GC, Pirali T, Genazzani AA. What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. J Med Chem 2021;64:4410-29. [PMID: 33847110 DOI: 10.1021/acs.jmedchem.1c00181] [Reference Citation Analysis]
24 von Kügelgen I. Molecular pharmacology of P2Y receptor subtypes. Biochem Pharmacol 2021;187:114361. [PMID: 33309519 DOI: 10.1016/j.bcp.2020.114361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Mesto N, Bailbe D, Eskandar M, Pommier G, Gil S, Tolu S, Movassat J, Tourrel-Cuzin C. Involvement of P2Y signaling in the restoration of glucose-induced insulin exocytosis in pancreatic β cells exposed to glucotoxicity. J Cell Physiol 2021. [PMID: 34435368 DOI: 10.1002/jcp.30564] [Reference Citation Analysis]
26 Zhou M, Wang W, Li Y, Zhang Q, Ji H, Li H, Hu Q. The role of P2Y6R in cardiovascular diseases and recent development of P2Y6R antagonists. Drug Discov Today 2020;25:568-73. [PMID: 31926135 DOI: 10.1016/j.drudis.2019.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Beamer E, Kuchukulla M, Boison D, Engel T. ATP and adenosine-Two players in the control of seizures and epilepsy development. Prog Neurobiol 2021;204:102105. [PMID: 34144123 DOI: 10.1016/j.pneurobio.2021.102105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Li F, Xu D, Hou K, Gou X, Li Y. The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells. J Thromb Thrombolysis 2020;50:874-85. [PMID: 32248335 DOI: 10.1007/s11239-020-02098-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
29 Erdling A, Johansson SE, Radziwon‐balicka A, Ansar S, Edvinsson L. Changes in P2Y 6 receptor‐mediated vasoreactivity following focal and global ischemia. Physiological Reports 2022;10. [DOI: 10.14814/phy2.15283] [Reference Citation Analysis]
30 Jovanovic S, Milenkovic I. Purinergic Modulation of Activity in the Developing Auditory Pathway. Neurosci Bull 2020;36:1285-98. [PMID: 33040238 DOI: 10.1007/s12264-020-00586-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
31 Glaser T, Andrejew R, Oliveira-Giacomelli Á, Ribeiro DE, Bonfim Marques L, Ye Q, Ren WJ, Semyanov A, Illes P, Tang Y, Ulrich H. Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease. Neurosci Bull 2020;36:1299-314. [PMID: 33026587 DOI: 10.1007/s12264-020-00582-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
32 Ollivier M, Beudez J, Linck N, Grutter T, Compan V, Rassendren F. P2X-GCaMPs as Versatile Tools for Imaging Extracellular ATP Signaling. eNeuro 2021;8:ENEURO. [PMID: 33380526 DOI: 10.1523/ENEURO.0185-20.2020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Dalghi MG, Montalbetti N, Carattino MD, Apodaca G. The Urothelium: Life in a Liquid Environment. Physiol Rev 2020;100:1621-705. [PMID: 32191559 DOI: 10.1152/physrev.00041.2019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
34 Barinov EF, Statinova EA, Sokhina VS, Faber TI. [Risks of progression of cerebrovascular pathology associated with the activity of the brain purinergic system]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:118-24. [PMID: 33244967 DOI: 10.17116/jnevro2020120101118] [Reference Citation Analysis]
35 Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I. P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation. Int J Mol Sci 2020;21:E1391. [PMID: 32092903 DOI: 10.3390/ijms21041391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
36 Zimmermann H. History of ectonucleotidases and their role in purinergic signaling. Biochem Pharmacol 2021;187:114322. [PMID: 33161020 DOI: 10.1016/j.bcp.2020.114322] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
37 Wirsching E, Fauler M, Fois G, Frick M. P2 Purinergic Signaling in the Distal Lung in Health and Disease. Int J Mol Sci 2020;21:E4973. [PMID: 32674494 DOI: 10.3390/ijms21144973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]